Shrunken pore syndrome in childhood cancer survivors treated with potentially nephrotoxic therapy

Esmee C. M. Kooijmansa Emma Children’s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, Amsterdam, The Netherlands;b Princess Máxima Center for Pediatric Oncology, Utrecht, The NetherlandsCorrespondence[email protected]

https://orcid.org/0000-0001-6961-1684 View further author information

Helena J. H. van der Palb Princess Máxima Center for Pediatric Oncology, Utrecht, The NetherlandsView further author information

Maxime C. F. Pilona Emma Children’s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, Amsterdam, The NetherlandsView further author information

Saskia M. F. Pluijmb Princess Máxima Center for Pediatric Oncology, Utrecht, The NetherlandsView further author information

Margriet van der Heiden-van der Loob Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands;c Dutch Childhood Oncology Group, Utrecht, The NetherlandsView further author information

Leontien C. M. Kremerb Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands;d Division of Child health, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands;e Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, Pediatric Oncology, Amsterdam, The NetherlandsView further author information

Dorine Brestersb Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands;f Willem Alexander Children’s Hospital/Leiden University Medical Center, Leiden, The NetherlandsView further author information

Eline van Dulmen-den Broedera Emma Children’s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, Amsterdam, The NetherlandsView further author information

Marry M. van den Heuvel-Eibrinkb Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands;d Division of Child health, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands;g Department of Pediatric Oncology, Sophia Children’s Hospital/Erasmus Medical Center, Rotterdam, The NetherlandsView further author information

Jacqueline J. Loonenh Department of Hematology, Radboud University Medical Center, Nijmegen, The NetherlandsView further author information

Marloes Louwerensi Department of Internal Medicine, Leiden University Medical Center, Leiden, The NetherlandsView further author information

Sebastian J. C. Neggersj Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The NetherlandsView further author information

Hanneke M. van Santenk Department of Pediatric Endocrinology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The NetherlandsView further author information

Wim J. E. Tissingb Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands;l Department of Pediatric Oncology, University of Groningen, University Medical Center Groningen, The NetherlandsView further author information

Andrica C. H. de Vriesb Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands;g Department of Pediatric Oncology, Sophia Children’s Hospital/Erasmus Medical Center, Rotterdam, The NetherlandsView further author information

Gertjan J. L. Kaspersa Emma Children’s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, Amsterdam, The Netherlands;b Princess Máxima Center for Pediatric Oncology, Utrecht, The NetherlandsView further author information

Margreet A. Veeninga Emma Children’s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, Amsterdam, The Netherlands;b Princess Máxima Center for Pediatric Oncology, Utrecht, The NetherlandsView further author information

Arend Bökenkampm Emma Children’s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Nephrology, Amsterdam, The NetherlandsView further author information

& on behalf of the Dutch LATER study group show all

Shrunken pore syndrome in childhood cancer survivors treated with potentially nephrotoxic therapy

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Shrunken pore syndrome in childhood cancer survivors treated with potentially nephrotoxic therapy

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date